World

Intismeran autogene developed to combat melanoma

by Lydia Liu
Sports Editor

Intismeran autogene, a personalized mRNA vaccine developed by Moderna and Merck, delivered strong results in a Phase Ⅲ trial for melanoma. Melanoma is a type of skin cancer that begins in melanocytes, the cells responsible for producing skin pigmentation. When mutations disrupt the mechanisms controlling these cells, they grow and divide uncontrollably, forming tumors. Although melanoma tumors can be surgically removed, cancer cells may remain elsewhere in the body, causing the disease to return or spread.

Because of their mutations, cancer cells can produce abnormal proteins called neoantigens. These proteins are not normally found on healthy cells, allowing T cells, immune cells that destroy altered cells, to recognize them. However, according to the National Cancer Institute, the tumor can suppress the immune system through pathways such as PD-1, limiting T-cell activity and allowing malignant cells to avoid being attacked.

Intismeran uses mRNA to help the immune system recognize a patient’s specific cancer. After surgeons remove a tumor, doctors analyze its mutations and identify neoantigens that could trigger an immune response. Doctors then create an individualized vaccine using mRNA that encodes these tumor-specific neoantigens. After the patient receives the vaccine, cells take up the mRNA and translate it into the encoded neoantigens. The immune system then recognizes the neoantigens and primes T-cells to target cancer cells that carry them. Merck reported that the vaccine can encode up to 34 tumor-specific neoantigens, allowing doctors to tailor the immune response to each patient. 

The vaccine is administered with Keytruda, an immunotherapy drug that blocks the PD-1 pathway. Together, the treatments strengthen the immune response while directing it toward cancer cells.

The Phase III trial included 1,137 patients with high-risk melanoma after surgeons removed their tumors. Patients received either Keytruda alone or Keytruda with intismeran. Those receiving the combination including intismeran stayed disease-free longer and were less likely to develop metastasis, or the spread of the disease to distant parts of the body.

Earlier Phase Ⅱ results also found that the combination reduced the risk of melanoma returning or death by 49% and the risk of distant metastasis or death by 59%.

However, intismeran has not yet received FDA approval. More data, including overall survival results, still needs to be collected and reviewed. Moderna and Merck plan to seek regulatory approval, potentially making the treatment available as early as 2027. The companies are also testing personalized mRNA vaccines for lung, bladder, and kidney cancers.

If regulators approve intismeran, the treatment could change how doctors treat melanoma. Rather than giving every patient the same therapy, doctors could use the mutations in each tumor to create a treatment specifically designed for that tumor. This could make personalized mRNA vaccines an important tool for keeping cancer in remission.

(Sources: Merck, Moderna, National Cancer Institute, and Reuters)

Categories: World

Leave a Reply